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A B S T R A C T
Background
Pain is a common feature of childhood and adolescence around the world, and for many young people, that pain is chronic. The
World Health Organization (WHO) guidelines for pharmacological treatments for persisting pain in children acknowledge that pain
in children is a major public health concern of high significance in most parts of the world. Views on children’s pain have changed over
time and relief of pain is now seen as important. In the past, pain was largely dismissed and was frequently left untreated, and it was
assumed that children quickly forgot about painful experiences.
We designed a suite of seven reviews in chronic non-cancer pain and cancer pain (looking at antidepressants, antiepileptic drugs,
non-steroidal anti-inflammatory drugs, opioids, and paracetamol as priority areas) to review the evidence for children’s pain using
pharmacological interventions.
As one of the leading causes of mortality and morbidity for children and adolescents in the world today, childhood cancer (and its
associated pain) is a major health concern. Specific mortality and morbidity data relating to children are not currently identified. All
childhood cancer rates are on the rise; for example, in the USA approximately 10,380 children aged under 15 years were expected to
be diagnosed with cancer by the end of 2016. However, with survival rates also increasing, over 80% of paediatric cancer patients are
expected to survive for five years or more, thus identifying the need to address pain management in this population.
Cancer pain in infants, children, and adolescents is primarily nociceptive pain with negative long term effects. Cancer-related pain is
generally caused directly by the tumour itself such as compressing on the nerve or inflammation of the organs. Cancer-related pain
generally occurs as a result of perioperative procedures, nerve damage caused by radiation or chemotherapy treatments, or mucositis.
However, this review focused on pain caused directly by the tumour itself such as nerve infiltration, external nerve compression, and
other inflammatory events.
Non-steroidal anti-inflammatory drugs (NSAIDs) are used to treat pain, reduce fever, and for their anti-inflammatory properties. They
are commonly used within paediatric pain management. NSAIDs are currently licensed for use in western countries, however not
approved for infants aged under three months. Primary adverse effects include gastrointestinal issues and possible renal impairment
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with long term use. Other adverse effects in children include diarrhoea, headache, nausea, constipation, rash, dizziness, and abdominal
pain.
Objectives
To assess the analgesic efficacy, and adverse events, of non-steroidal anti-inflammatory drugs (NSAIDs) used to treat cancer-related
pain in children and adolescents aged from birth and 17 years, in any setting.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) via the Cochrane Register of Studies Online, MEDLINE
via Ovid, and Embase via Ovid from inception to 21 February 2017. We also searched the reference lists of retrieved studies and
reviews, and searched online clinical trial registries.
Selection criteria
Randomised, double-blind trials of any dose, and any route, treating cancer-related pain in children and adolescents, comparing
NSAIDs with placebo or an active comparator.
Data collection and analysis
Two review authors independently assessed studies for eligibility.We planned to use dichotomous data to calculate risk ratio and number
needed to treat for one additional event, using standard methods. We assessed GRADE (Grading of Recommendations Assessment,
Development and Evaluation) and planned to create a ’Summary of findings’ table.
Main results
No studies were eligible for inclusion in this review (very low quality evidence). We downgraded the quality of evidence by three levels
due to the lack of data reported for any outcome.
Authors’ conclusions
There is no evidence from randomised controlled trials that non-steroidal anti-inflammatory drugs (NSAIDs) reduce cancer-related
pain in children and adolescents. This means that no reliance or conclusions can be made about efficacy or harm in the use of NSAIDs
to treat chronic cancer-related pain in children and adolescents.
P L A I N L A N G U A G E S U M M A R Y
NSAIDs for cancer-related pain in children and adolescents
Bottom line
We are uncertain whether NSAIDs will provide pain relief for cancer-related pain in children or adolescents.
Background
Childhood cancer is one of the leading causes of disease and death for children and adolescents in the world today. Its associated pain
is a major health concern and specific data for children are not currently well known.
Cancer pain in infants, children, and adolescents is primarily nerve pain with negative long term effects. Cancer-related pain is generally
caused directly by the tumour itself such as nerve infiltration, external nerve compression, and other inflammatory events.
NSAIDs are used to treat pain or reduce fever, and are commonly used in children. NSAIDs are currently licensed for use in western
countries, but they are not approved for infants aged under three months. The key side effects of NSAIDs are stomach problems and
possible damage to kidneys following long term use. Other side effects in children include diarrhoea, headache, nausea, constipation,
rash, dizziness, flatulence, stomach pain, and indigestion.
Key results
In February 2017 we searched for randomised controlled clinical trials where any NSAIDs were used to treat any cancer-related pain
in people aged from birth to 17 years. We found no studies that met the requirements for this review. Several studies tested NSAIDs
on adults in chronic pain, but none in participants aged from birth to 17 years.
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Quality of the evidence
We rated the quality of the evidence from studies using four levels: very low, low, moderate, or high. Very low quality evidence means
that we are very uncertain about the results. High quality evidence means that we are very confident in the results.
We rate the overall quality of evidence to be very low quality evidence due to a lack of information, meaning there is no evidence to
support or refute the use of NSAIDs.
B A C K G R O U N D
Pain is a common feature of childhood and adolescence around
the world, and for many young people, that pain is chronic. The
World Health Organization (WHO) guidelines for pharmacolog-
ical treatments for persisting pain in children acknowledge that
pain in children is a major public health concern of high signif-
icance in most parts of the world (WHO 2012). Views on chil-
dren’s pain have changed over time and relief of pain is now seen
as important. In the past, pain was largely dismissed and was fre-
quently left untreated, and it was assumed that children quickly
forgot about painful experiences. Since the 1970s, studies com-
paring child and adult pain management revealed a variety of re-
sponses to pain, fuelling the need to focus on paediatric pain in
more depth (Caes 2016).
Infants (birth to 12 months), children (1 to 9 years), and adoles-
cents (10 to 18 years) (WHO 2012) account for 27% (1.9 billion)
of the world’s population (United Nations 2017), and the propor-
tion of those aged up to 14 years varies from 12% (in Hong Kong)
to 50% (in Niger) (World Bank 2016). However, we know little
about the pain management needs of this population. For exam-
ple, in the Cochrane Library, approximately 12 reviews produced
by the Cochrane Pain, Palliative and Supportive Care (PaPaS) Re-
view Group in the past 18 years have been specifically concerned
with children and adolescents, compared to over 100 reviews spe-
cific to adults. Additional motivating factors for investigating chil-
dren’s pain include the vast amount of unmanaged pain in the
paediatric population and new technologies and treatments being
developed. We convened an international group of leaders in pae-
diatric pain to design a suite of seven reviews in chronic pain and
cancer pain (looking at antidepressants, antiepileptic drugs, non-
steroidal anti-inflammatory drugs (NSAIDs), opioids, and parac-
etamol as priority areas) to review the evidence under a programme
grant for children’s pain using pharmacological interventions in
children and adolescents (Appendix 1).
This review is based on a template for reviews of pharmacothera-
pies used to relieve pain in infants, children and adolescents. The
aim is for all reviews to use the same methods, based on new cri-
teria for what constitutes reliable evidence (Moore 2010a; Moore
2012; Appendix 2). This review focuses on NSAIDs to treat can-
cer pain.
Description of the condition
This review focused on pain that children and adolescents experi-
ence as a result of any type of cancer.
The type of cancer pain in infants, children and adolescents is pri-
marily nociceptive pain (Ljungman 1996), and generally occurs as
a result of perioperative procedures and treatments. In addition,
nerve damage caused by radiation or chemotherapy (WHO 2012)
is also common. However, the tumour itself can also cause nerve
infiltration, external nerve compression, and other painful inflam-
matory events such as distention (WHO 2012).
Whilst diagnostic andperioperative procedures performed for can-
cer treatment are a known common cause of pain in these patients
(Ripamonti 2008), this review did not cover perioperative pain or
adverse effects of treatments such asmucositis. We focused on pain
caused directly by the tumour itself such as tissue damage, nerve
infiltration, external nerve compression and other inflammatory
events.
As one of the leading causes of mortality and morbidity in the
world today, childhood cancer (and its associated pain) is a major
health concern. The WHO predicts 14 to 15 million new cases of
cancer across all ages to arise by 2020 (Frankish 2003; Ripamonti
2008), accounting for approximately 8.2milliondeathsworldwide
(WHO 2011). Specific mortality and morbidity data relating to
children were not identified.
Worldwide childhood cancer statistics are difficult to estimate, par-
ticularly when examining both developed and developing coun-
ties. However, cancer is the leading cause of death in devel-
oped countries (WHO 1998). In the European region, leukaemia
(34.1%), central nervous system (CNS) tumours (22.6%), and
lymphomas (11.5%) are the largest cancer diagnostic groups in
the paediatric population (birth to 15 years) (Kaatsch 2010). In
the USA, childhood cancer is the second leading cause of death
(excluding neonates) (after injury), with leukaemia (30%), CNS
tumours or brain and other CNS tumours (26%), and neuroblas-
toma (6%) as the leading types of diagnosed cancers (ACS 2015).
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All childhood cancer rates are on the rise; for example, in the USA
approximately 10,380 children under the age of 15 years were
expected to be diagnosed with cancer by the end of 2016 (ACS
2015). However, with survival rates also increasing, over 80% of
paediatric cancer patients are expected to survive for five years or
more (ACS2015). In the developingworld, the incidence of cancer
is difficult to estimate due to poor reporting, diagnostic facilities
and hospital statistics. It is known that Burkitt lymphoma, non-
Hodgkin lymphoma, nephroblastoma, retinoblastoma, and rhab-
domyosarcoma are among the most common cancers in children
across African regions (Tanko 2009). In Asian regions, leukaemias
and CNS tumours are among the most common childhood can-
cers (IARC 2008).
Description of the intervention
NSAIDs are used for the treatment of pain and fever reduction
for their anti-inflammation properties. They are commonly used
within paediatric pain management (Blanca-López 2015). The
two main types of NSAIDs are selective and nonselective, which
refer to the ability of the NSAID to inhibit specific types of COX
enzymes (Misurac 2013). NSAIDs are currently licensed for use
in western countries, but are not approved for infants aged under
three months (WHO 2012). NSAIDs are also widely used for
patent ductus arteriosus (PDA) closure in neonates.
Currently available NSAIDs include: aceclofenac, acetylsali-
cylic acid, celecoxib, choline magnesium trisalicylates diclofenac,
etodolac, etoricoxib, fenoprofen, ibuprofen, indometacin, ke-
toprofen, ketorolac, mefenamic acid, meloxicam, nabume-
tone, naproxen, parecoxib, phenylbutazone, piroxicam, sulindac,
tenoxicam, and tiaprofenic acid (BNF 2016).
NSAIDs are used in a variety of doses and are commonly prescribed
to children with pain as an oral tablet or liquid formulation. The
recommended dose for ibuprofen (for example) is 5 to 10 mg/kg
every six to eight hours with a maximum daily dose of 1200 mg.
Additionally, for naproxen, a maximum dose of 1000 mg per day
is recommended (WHO 2012). The recommendation for paedi-
atric patients is to use the lowest dose, for the shortest duration
possible to control symptoms (NICE 2015); hence, NSAIDs are
also used in conjunction with paracetamol to reduce the amount
administered to children (WHO 2012).
The two primary adverse effects of NSAIDs are renal impair-
ment and gastrointestinal issues (NICE 2015). Common side ef-
fects in children include diarrhoea, headache, nausea, constipa-
tion, rash, dizziness, flatulence, abdominal pain, and dyspepsia
(WHO 2012). Other adverse effects include hepatic function im-
pairment, contraindications with allergic disorders (hypersensitiv-
ity to aspirin, asthma, angioedema, urticaria, rhinitis), cardiac im-
pairment, Reye’s syndrome, antiplatelet effects, coagulation de-
fects, and dangerous environmental harms (particularly seen in di-
clofenac). The long-term safety of the use of NSAIDs in children
is unclear (Blanca-López 2015). However, some safety assessments
of ibuprofen in children have been compared with paracetamol
and not found a significant increased risk in serious adverse events
or main causes of hospitalisation (acute gastrointestinal bleeding,
acute renal failure, anaphylaxis, or Reye’s syndrome) (Lesko 1995;
Lesko 1997; Lesko 1999).
How the intervention might work
One current hypothesis is that damage to the peripheral nerves
is followed by an inflammatory reaction that relates to increased
production of prostaglandins, amplifying sodium currents and
calcium influx in peripheral nociceptive neurons, and enhancing
neurotransmitter release in theCNS and depolarisation of second-
order nociceptive neurons (Vo 2009). Preclinical data suggest an
immune pathogenesis of neuropathic pain, but clinical evidence
of a central role of the immune system is less clear (Calvo 2012).
NSAIDs inhibit the production of prostaglandins, and thus could
lessen the peripheral and central sensory hypersensitivity that oc-
curs with nerve injury-associated inflammation. NSAIDs have
been shown to reduce sensory hypersensitivity in animal models
(Hasnie 2007; Kawakami 2002).
Why it is important to do this review
The paediatric population is at risk of inadequate management
of pain (AMA 2013). Some conditions that would be aggressively
treated in adults are being managed with insufficient analgesia in
the younger populations (AMA 2013). Although there have been
repeated calls for best evidence to treat children’s pain, such as
Eccleston 2003, there are no easily available summaries of themost
effective paediatric pain relief.
This Cochrane Review will form part of a Programme Grant to
address the unmet needs of people with chronic pain, commis-
sioned by the National Institute for Health Research (NIHR) in
the UK. This topic was identified in June 2015 during consulta-
tion with experts in paediatric pain. Please see Appendix 1 for full
details of the meeting. The standards used to assess evidence in
chronic pain trials have changed substantially in recent years, with
particular attention being paid to trial duration, withdrawals, and
statistical imputation following withdrawal, all of which can sub-
stantially alter estimates of efficacy. The most important change
is to encourage a move from using average pain scores, or average
change in pain scores, to the number of people who have a large
decrease in pain (by at least 50%). Pain intensity reduction of 50%
or more has been shown to correlate with improvements in co-
morbid symptoms, function, and quality of life (Moore 2011a).
These standards are set out in the reference guide for pain studies
(AUREF 2012).
O B J E C T I V E S
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To assess the analgesic efficacy, and adverse events, of non-steroidal
anti-inflammatory drugs (NSAIDs) used to treat cancer-related
pain in children and adolescents aged from birth to 17 years, in
any setting.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We planned to only include randomised controlled trials (RCTs),
with or without blinding, and participant or observer reported
outcomes.
Full journal publication was required, with the exception of online
clinical trial results, summaries of otherwise unpublished clinical
trials and abstracts with sufficient data for analysis. We planned to
include studies published in any language. We excluded abstracts
(usually meeting reports) or unpublished data, non-randomised
studies, studies of experimental pain, case reports, and clinical
observations.
Types of participants
Weplanned to include studies of infants, children, and adolescents
aged from birth to 17 years, who have (one or more) cancer and
experience pain directly related to the condition.
We planned to include studies of participants with more than one
type of cancer pain, and to analyse results according to the primary
condition.
We excluded studies of perioperative pain, short-term infection
pain, short-term injury or trauma pain, acute pain, functional
abdominal pain, burn pain, musculoskeletal pain, headache and
migraine, sickle cell disease acute crisis pain, mucositis, or any
other chronic non-cancer pain.
Types of interventions
We planned to include studies reporting interventions prescribing
NSAIDs for the relief of cancer pain; by any route, in any dose,
with comparison to a placebo or any active comparator.
Types of outcome measures
Studies had to report pain assessment as either a primary or sec-
ondary outcome to be eligible for inclusion in this review, as well
as meeting the other selection criteria.
We planned to include trials measuring pain intensity and pain
relief assessed using validated tools such as numerical rating scale
(NRS), visual analogue scale (VAS), Faces Pain Scale - Revised
(FPS-R), Colour Analogue Scale (CAS), or any other validated
rating scale.
We were particularly interested in Paediatric Initiative on Meth-
ods, Measurement, and Pain Assessment in Clinical Trials (Ped-
IMMPACT) definitions for moderate and substantial benefit in
chronic pain studies (PedIMMPACT 2008). These are defined as:
at least 30% pain relief over baseline (moderate); at least 50% pain
relief over baseline (substantial); much or very much improved
on Patient Global Impression of Change scale (PGIC; moderate);
very much improved on PGIC (substantial).
These outcomes are different from those used in most earlier re-
views, concentrating as they do on dichotomous outcomes where
pain responses do not follow a normal (Gaussian) distribution.
People with chronic pain desire high levels of pain relief, ideally
more than 50% pain intensity reduction, and ideally having no
worse than mild pain (Moore 2013a; O’Brien 2010).
We also planned to record any reported adverse events. We also
planned to report the timing of outcome assessments.
Primary outcomes
1. Participant-reported pain relief of 30% or greater.
2. Participant-reported pain relief of 50% or greater.
3. PGIC much or very much improved.
In the absence of self-reported pain, we planned to consider the
use of ’other-reported’ pain, typically an observer such as a parent,
carer, or healthcare professional (Stinson 2006; Von Baeyer 2007).
Secondary outcomes
We identified the following with reference to the PedIMMPACT
recommendations, which suggest core outcome domains andmea-
sures for consideration in paediatric acute and chronic/recurrent
pain clinical trials (PedIMMPACT 2008):
1. carer global impression;
2. requirement for rescue analgesia;
3. sleep duration and quality;
4. acceptability of treatment;
5. physical functioning as defined by validated scales;
6. quality of life as defined by validated scales;
7. any adverse events;
8. withdrawals due to adverse events; and
9. any serious adverse event. Serious adverse events typically
include any untoward medical occurrence or effect that at any
dose results in death, is life-threatening, requires hospitalisation
or prolongation of existing hospitalisation, results in persistent or
significant disability or incapacity, is a congenital anomaly or
birth defect, is an ’important medical event’ that may jeopardise
the patient, or may require an intervention to prevent one of the
above characteristics or consequences.
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Search methods for identification of studies
The authors and Information Specialist developed the search strat-
egy, based on previous strategies used within the PaPaS Review
Group, and we carried out the searches. We also sought advice
from the Cochrane Childhood Cancer Group.
Electronic searches
We searched the following databases:
• Cochrane Central Register of Controlled Trials
(CENTRAL) (via the Cochrane Library) searched on 21/2/2017;
• MEDLINE (via Ovid) 1947 to February week 2 2017;
• Embase (via Ovid) 1974 to 21/2/2017.
We used medical subject headings (MeSH) or equivalent and text
word terms. We restricted our search for RCTs and clinical trials.
There were no language restrictions. There were no date restric-
tions. The focus of the key words in our search terms was on cancer
pain and NSAIDs. Searches were tailored to individual databases.
The search strategies for MEDLINE, Embase and CENTRAL are
presented in Appendix 3; Appendix 4 and Appendix 5 respectively.
Searching other resources
We searched clinicaltrials.gov (www.clinicaltrials.gov) and the
WHO International Clinical Trials Registry Platform (ICTRP) (
apps.who.int/trialsearch/) on 21 February 2017 for ongoing tri-
als. In addition, we checked reference lists of reviews and retrieved
articles for additional studies, and performed citation searches on
key articles. We planned to contact experts in the field for unpub-
lished and ongoing trials. We planned to contact study authors
where necessary for additional information.
Data collection and analysis
We planned to perform separate analyses according to particular
types of cancer. We planned to combine different cancer types in
analyses for exploratory purposes only.
Selection of studies
Two review authors independently determined eligibility by read-
ing the abstract of each study identified by the search. Indepen-
dent review authors eliminated studies that clearly did not satisfy
inclusion criteria, and obtained full copies of the remaining stud-
ies. Two review authors read these studies independently to select
relevant studies, and in the event of disagreement, a third author
adjudicated. We did not anonymise the studies in any way before
assessment. We included a PRISMA flow chart in the full review
which shows the status of identified studies (Moher 2009) as rec-
ommended in part 2, section 11.2.1 of the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011).We planned
to include studies in the review irrespective of whether measured
outcome data were reported in a ‘usable’ way.
Data extraction and management
We planned to obtain full copies of the studies and two authors
planned to independently carry out data extraction. Where avail-
able, data extraction would include information about the type
of cancer, number of participants treated, drug and dosing regi-
men, study design (placebo or active control), study duration and
follow-up, analgesic outcome measures and results, withdrawals,
and adverse events (participants experiencing any adverse event,
or serious adverse event). We planned to collate multiple reports
of the same study, so that each study rather than each report was
to be the unit of interest in the review. We planned to collect char-
acteristics of the included studies in sufficient detail to populate a
‘Characteristics of included studies’ table.
We planned to use a template data extraction form and check for
agreement before entry into Cochrane’s statistical software Review
Manager (version 5.3) (Review Manager 2014).
If a study hadmore than two intervention arms,we planned to only
include in the review intervention groups and control groups that
met the eligibility criteria. If multi-arm studies were included, we
planned to analyse multiple intervention groups in an appropriate
way to avoid arbitrary omission of relevant groups and double-
counting of participants.
Assessment of risk of bias in included studies
Two authors planned to independently assess risk of bias for each
study, using the criteria outlined in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011).
We planned to complete a ’Risk of bias’ table for each included
study using the ’Risk of bias’ tool in RevMan (Review Manager
2014).
We planned to assess the following for each study. Any disagree-
ments were to be resolved by discussion between review authors
and where necessary, a third review author.
1. Random sequence generation (checking for possible
selection bias). We planned to assess the method used to generate
the allocation sequence as: low risk of bias (ie, any truly random
process, for example random number table; computer random
number generator); or unclear risk of bias (when the method
used to generate the sequence was not clearly stated). We
excluded studies at high risk of bias that used a non-random
process (eg, odd or even date of birth; hospital or clinic record
number).
2. Allocation concealment (checking for possible selection
bias). The method used to conceal allocation to interventions
prior to assignment determines whether intervention allocation
could have been foreseen in advance of, or during, recruitment,
or changed after assignment. We planned to assess the methods
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as: low risk of bias (eg, telephone or central randomisation;
consecutively numbered, sealed, opaque envelopes); or unclear
risk of bias (when the method was not clearly stated). We
excluded studies that did not conceal allocation and were
therefore at a high risk of bias (eg, open list).
3. Blinding of participants and personnel (checking for
possible performance bias). We planned to assess any methods
used to blind the participants and personnel from knowledge of
which intervention a participant received. We planned to assess
the methods as: low risk of bias (study stated that the
participants and personnel involved were blinded to treatment
groups); unclear risk of bias (study did not state either way as to
whether participants and personnel were blinded to treatment
groups); or high risk of bias (participants or personnel were not
blinded) (as stated in Types of studies, we planned to still include
trials, with or without blinding, and participant or observer
reported outcomes).
4. Blinding of outcome assessment (checking for possible
detection bias). We planned to assess any methods used to blind
the outcome assessors from knowledge of which intervention a
participant received. We planned to assess the methods as: low
risk of bias (eg study stated that it was single-blinded and
described the method used to achieve blinding of the outcome
assessor); unclear risk of bias (study stated that outcome assessors
were blinded but did not provide an adequate description of how
it was achieved); or high risk of bias (outcome assessors were not
blinded) (as stated in Types of studies, we planned to still include
trials, with or without blinding, and participant or observer
reported outcomes).
5. Incomplete outcome data (checking for possible attrition
bias due to the amount, nature, and handling of incomplete
outcome data). We planned to assess the methods used to deal
with incomplete data as: low risk of bias (ie fewer than 10% of
participants did not complete the study or used ’baseline
observation carried forward’ (BOCF) analysis, or both); unclear
risk of bias (used ’last observation carried forward’ (LOCF)
analysis); or high risk of bias (used ’completer’ analysis).
6. Selective reporting (checking for possible reporting bias).
We planned to assess the methods used to report the outcomes of
the study as: low risk of bias (if all planned outcomes in the
protocol or methods were also reported in the results); unclear
risk of bias (if there was not a clear distinction between planned
outcomes and reported outcomes); high risk of bias (if some
planned outcomes from the protocol or methods were clearly left
out of the results).
7. Size of study (checking for possible biases confounded by
small size). We planned to assess studies as being at low risk of
bias (200 participants or more per treatment arm); unclear risk
of bias (50 to 199 participants per treatment arm); or high risk of
bias (fewer than 50 participants per treatment arm).
8. Other bias. We planned to assess studies for any additional
sources of bias as low, unclear or high, and provide rationale.
Measures of treatment effect
Where dichotomous data were available, we planned to calcu-
late a risk ratio (RR) with 95% confidence intervals (CIs) and
meta-analyse the data as appropriate. We planned to calculate
numbers needed to treat for an additional beneficial outcome
(NNTBs) where appropriate (McQuay 1998); for unwanted ef-
fects the NNTB becomes the number needed to treat for an ad-
ditional harmful outcome (NNTH) and is calculated in the same
manner. Where continuous data were reported, we planned to use
appropriate methods to combine these data in the meta-analysis.
Unit of analysis issues
We planned to accept randomisation to the individual participant
only. We planned to split the control treatment arm between ac-
tive treatment arms in a single study if the active treatment arms
were not combined for analysis. We only accepted studies with a
minimum 10 participants per treatment arm.
Dealing with missing data
Weplanned to use intention-to-treat (ITT) analysis where the ITT
population consisted of participants who were randomised, took
at least one dose of the assigned study medication, and provided at
least one post-baseline assessment. We planned to assign missing
participants zero improvement wherever possible.
Assessment of heterogeneity
We planned to identify and measure heterogeneity as recom-
mended in chapter 9 of the Cochrane Handbook for Systematic Re-
views of Interventions (Higgins 2011). We planned to deal with
clinical heterogeneity by combining studies that examined similar
conditions. We planned to undertake and present a meta-analy-
sis only if participants, interventions, comparisons, and outcomes
were judged to be sufficiently similar to ensure an answer that is
clinically meaningful. We planned to assess statistical heterogene-
ity visually (L’Abbé 1987), and with the use of the I² statistic.
When I² was greater than 50%, we planned to consider the pos-
sible reasons.
Assessment of reporting biases
We planned to assess the risk of reporting bias, as recommended
in chapter 8 of the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011).
The aim of this reviewwas to use dichotomous outcomes of known
utility and value to patients (Hoffman 2010;Moore 2010b;Moore
2010c; Moore 2010d; Moore 2013a). The review did not depend
on what the authors of the original studies chose to report or not,
although clearly difficulties were predicted to arise in studies that
failed to report any dichotomous results. We planned to extract
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and use continuous data, which may reflect efficacy and utility
poorly, and may have been useful for illustrative purposes only.
We planned to assess publication bias using a method designed to
detect the amount of unpublished data with a null effect required
to make any result clinically irrelevant (usually taken to mean a
number needed to treat (NNT) of 10 or higher; Moore 2008).
Data synthesis
We planned to use a fixed-effect model for meta-analysis. We
planned to use a random-effects model for meta-analysis if there
was significant clinical heterogeneity and it was considered appro-
priate to combine studies. We planned to conduct our analysis
using the primary outcomes of pain and adverse events, and we
planned to calculate theNNTHs for adverse events.Weplanned to
use the Cochrane software program Review Manager 5.3 (Review
Manager 2014).
Quality of evidence
To analyse data, two review authors planned to independently
rate the quality of each outcome.We planned to use the GRADE
approach to assess the quality of the body of the evidence related
to each of the key outcomes, and report our judgement on the
quality of the evidence in the ’Summary of findings’ table (chapter
12, Higgins 2011; Appendix 6).
In addition, there may have been circumstances where the overall
rating for a particular outcome needed to be adjusted as recom-
mended by GRADE guidelines (Guyatt 2013a). For example, if
there were so few data that the results were highly susceptible to
the random play of chance, or if studies used LOCF imputation in
circumstances where there were substantial differences in adverse
event withdrawals, one would have no confidence in the result,
and would need to downgrade the quality of the evidence by three
levels, to very low quality. In circumstances where there were no
data reported for an outcome, we planned to report the level of
evidence as no evidence to support or refute (Guyatt 2013b).
’Summary of findings’ table
We planned to include a ’Summary of findings’ table as set out
in the Cochrane PaPaS Review Group’s author guide (AUREF
2012), and recommended in theCochraneHandbook for Systematic
Reviews of Interventions, chapter 4.6.6 (Higgins 2011).Weplanned
to justify and document all assessments of the quality of the body
of evidence.
In an attempt to interpret reliability of the findings for this sys-
tematic review, we planned to assess the summarised data using
the GRADE guidelines (Appendix 6) to rate the quality of evi-
dence (Guyatt 2011) of each of the key outcomes listed in Types
of outcome measures (chapter 12, Higgins 2011), as appropriate.
Using the explicit criteria against: study design, risk of bias, im-
precision, inconsistency, indirectness, and magnitude of effect, we
planned to summarise the evidence in an informative, transparent
and succinct ’Summary of findings’ table or ’Evidence profile’ ta-
ble (Guyatt 2011).
Subgroup analysis and investigation of heterogeneity
We planned to perform subgroup analyses where a minimum
number of data were available (at least 200 participants per treat-
ment arm). We planned to analyse according to age group; type
of drug; geographical location or country; type of control group;
baseline measures; frequency, dose and duration of drugs; nature
of drug.
We planned to investigate whether the results of subgroups were
significantly different by inspecting the overlap of confidence in-
tervals and performing the test for subgroup differences available
in RevMan.
Sensitivity analysis
We did not plan to carry out any sensitivity analysis because the
evidence base was known to be too small to enable reliable analy-
sis; we did not plan to pool results from cancer pain of different
origins in the primary analyses. We planned to examine details of
dose escalation schedules in the unlikely situation that this could
provide some basis for a sensitivity analysis.
R E S U L T S
Description of studies
Results of the search
A PRISMA flow diagram of the search results is shown in Figure
1.
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Figure 1. Study flow diagram.
Searches of the three main databases revealed 4813 records of
titles and abstracts, of which we removed 1415 duplicates. We also
searched clinicaltrials.gov and app.who.int/trialsearch/ and found
no additional eligible studies.
We screened the remaining 3398 titles and abstracts for eligibility,
of which we removed 3389 as ineligible studies.
Of the remaining nine studies we retrieved the full text articles,
and excluded all nine. No ongoing studies were identified. No
studies fulfilled the eligibility criteria, nor were any eligible to be
entered into a quantitative analysis.
Included studies
No studies met our inclusion criteria for this review.
Excluded studies
See Characteristics of excluded studies.
We excluded nine studies in this review.
Upon reading the full texts, we discovered three studies were in
adult populations (Cappelaere 1971; Harris 2003; Toscani 1994),
and one investigated participants whose ages ranged from 5 to
69 years; however, subunit data were not available (Mercandante
1999). Five studies were not RCTs (Bottner 2001; Gross 2003;
Lauretti 1998; Sittl 1991; Zhen 2007).
Risk of bias in included studies
Because no studies were eligible for inclusion we could not assess
the efficacy of NSAIDs for treating cancer-related pain in children
and adolescents.
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Effects of interventions
No studies were eligible for inclusion in this review, therefore, we
could not assess the efficacy of NSAIDs to treat cancer-related
pain in children and adolescents. We downgraded the quality of
evidence by three levels to very low due to the lack of data reported
for any outcome.
D I S C U S S I O N
Summary of main results
We found no randomised controlled trials (RCTs) for inclusion
in this review. There are no data from RCTs to inform assessment
of the effectiveness of NSAIDs in treating cancer-related pain in
children and adolescents. NSAIDs are used in adults alongside
other analgesics as they are thought to be useful for bone pain.
There is currently no high quality evidence for their use (Derry
2017).
Overall completeness and applicability of
evidence
As no RCTs could be identified we were unable to comment about
efficacy or harm from the use of NSAIDs to treat cancer-related
pain in children and adolescents. Similarly, we could not comment
on our remaining secondary outcomes: carer global impression of
change; requirement for rescue analgesia; sleep duration and qual-
ity; acceptability of treatment; physical functioning; and quality
of life.
The suite of reviews
This review is part of a suite of reviews on pharmacological in-
terventions for chronic pain and cancer-related pain in children
and adolescents (Appendix 1). Taking a broader view on this suite
of reviews, some pharmacotherapies (investigated in our other re-
views) are likely to providemore data than others. Thus, the results
were as expected considering that RCTs in children are known to
be limited. The results have the potential to assist to inform policy
making decisions for funding future clinical trials into NSAID
treatment of child and adolescent pain, therefore, any results (large
or small) are important to capture a snapshot of the current evi-
dence for NSAIDs.
Quality of the evidence
We rated the quality of evidence as very low.
We were unable to find any published RCTs to support or refute
the use of NSAIDs to treat cancer-related pain in children and
adolescents. We were unable to examine any adverse effects.
This review may represent a case of absence of evidence rather
than evidence of absence. While it may be true that the absence
of evidence may reflect that NSAIDs per se are inadequately ef-
fective and their use as monotherapy analgesics is more likely to
cause harm than benefit, the opposite may also pertain as data are
lacking. It is difficult to conduct long-term RCTs in children with
cancer-related pain, and few observational/clinical data have been
published.
Potential biases in the review process
We carried out extensive searches of major databases using broad
search criteria, and also searched two large clinical trial registries.
We think it is unlikely that we have missed relevant studies.
Agreements and disagreements with other
studies or reviews
We were not able to identify any published systematic reviews on
this topic.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
General
We identified no randomised controlled trials (RCTs), to support
or refute the use of NSAIDs to treat cancer-related pain in children
and adolescents.
This is disappointing as children and adolescents have specific
needs for analgesia. Extrapolating from adult data may be possible
but could compromise effectiveness and safety.
Despite the lack of evidence of long-term effectiveness and safety,
we know that clinicians prescribe NSAIDs to children and ado-
lescents when medically necessary, based on extrapolation from
adult guidelines (for example, the recent CDCGuidelines, Dowell
2016), when perceived benefits in conjunction with other multi-
modalities improve a child’s care. The evidence for the use of
NSAIDs for cancer pain in adults is low quality (Derry 2017)
In current practice, despite the lack of high quality evidence,
NSAIDs are given to young children and adolescents based on
clinical knowledge and experience.
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For children with cancer-related pain
Children and adolescents experiencing cancer pain need to be ade-
quately treated, despite there being little good evidence around the
use of NSAIDs for treating cancer-related pain. At present, treat-
ment is based on clinical experience, extrapolation from evidence
and experience in adults, and advice from respected authorities.
No judgment can be made about adverse events or withdrawals.
For clinicians
Children and adolescents experiencing cancer pain need to be ade-
quately treated, despite there being little good evidence around the
use of NSAIDs for treating cancer-related pain. At present, treat-
ment is based on clinical experience, extrapolation from evidence
and experience in adults, and advice from respected authorities.
No judgment can be made about adverse events or withdrawals.
For policy makers
Children and adolescents experiencing cancer pain need to be ade-
quately treated, despite there being little good evidence around the
use of NSAIDs for treating cancer-related pain. At present, treat-
ment is based on clinical experience, extrapolation from evidence
and experience in adults, and advice from respected authorities.
No judgment can be made about adverse events or withdrawals.
For funders
Children and adolescents experiencing cancer pain need to be ade-
quately treated, despite there being little good evidence around the
use of NSAIDs for treating cancer-related pain. At present, treat-
ment is based on clinical experience, extrapolation from evidence
and experience in adults, and advice from respected authorities.
No judgment can be made about adverse events or withdrawals.
Implications for research
General
Theheterogenous nature of pain in childrenneeds to be recognised
and presents challenges in designing research studies. In addition,
children experience fewer solid tumours and so generally do not
experience pain from that source.
Overall, there appears to be a gap between what is done in practice
and what is investigated in prospective clinical trials for treating
children’s and adolescents’ pain with NSAIDs.
The lack of evidence highlighted in this review implies there is a
need to fund and support suitable research for the treatment of
cancer-related pain in children and adolescents using NSAIDs.
Design
Several methodological issues stand out.
The first is the use of outcomes of value to children with cancer
pain. Existing trials are designed more for purposes of registration
andmarketing than informing and improving clinical practice, of-
ten because the outcomes chosen are average pain scores, or statis-
tical differences, and rarely howmany children achieve satisfactory
pain relief. In the situation where initial pain is mild or moderate,
some consideration needs to be given to what constitutes a satis-
factory outcome. The situation is somewhat different to that of
strong opioids in cancer pain that are used for moderate to severe
pain.
The second is the time taken to achieve good pain relief. We have
no information aboutwhat constitutes a reasonable time to achieve
a satisfactory result. Initially this may best be approached with a
Delphi methodology involving children and their carers.
The third is design. Studies with cross-over design often have sig-
nificant attrition. Parallel group designs may be preferable.
The fourth is size. The studies need to be suitably powered to
ensure adequate data after the effect of attrition due to various
causes.Much larger studies of several hundredparticipants ormore
are needed. This may require a multicentre approach.
There are some other design issues that might be addressed. Most
important might well be a clear decision concerning the gold-stan-
dard treatment comparator. Placebo-controlled studies in cancer
pain are unlikely to be ethically feasible. It may be that low dose
oral morphine is a suitable comparator, as a suggested alternative
treatment for mild to moderate pain.
An alternative approach might be to design large registry studies.
This could provide an opportunity to foster collaboration among
paediatric clinicians and researchers to create an evidence base.
Measurement (endpoints)
Trials need to consider additional endpoints of no worse thanmild
pain as well as the standard approaches to pain assessment.
Other
Prospective randomised trials is the obvious design of choice,
but other pragmatic designs may be worth considering. Studies
could incorporate initial randomisation, but a pragmatic design
to provide immediately-relevant information on effectiveness and
costs. Such designs in pain conditions have been published (Moore
2010e).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bottner 2001 Allocation: not RCT.
Cappelaere 1971 Population: adults.
Gross 2003 Intervention: case study, not RCT.
Harris 2003 Population: adults.
Lauretti 1998 Intervention: case study, not RCT.
Mercandante 1999 Population: Age range 5 to 69 years. Attempted contact for subunit data
Sittl 1991 Allocation/study design: not RCT.
Toscani 1994 Population: adults.
Zhen 2007 Allocation/study design: not an RCT.
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D A T A A N D A N A L Y S E S
This review has no analyses.
A P P E N D I C E S
Appendix 1. Meeting for NIHR Programme Grant agenda on pain in children
Date
Monday 1st June 2015
Location
International Association of the Study of Pain (IASP) Conference, Seattle, USA
Delegates
AllenFinlay, AnnaErskine, BorisZernikow,ChantalWood,Christopher Eccleston, ElliotKrane,GeorgeChalkaiadis,GustavLjungman,
Jacqui Clinch, Jeffrey Gold, Julia Wager, Marie-Claude Gregoire, Miranda van Tilburg, Navil Sethna, Neil Schechter, Phil Wiffen,
Richard Howard, Susie Lord.
Purpose
National Institute for Health Research (NIHR) (UK) Programme Grant - Addressing the unmet need of chronic pain: providing the
evidence for treatments of pain.
Proposal
Nine reviews in pharmacological interventions for chronic pain in children and adolescents: Children (5 new, 1 update, 1 overview, and
2 rapid) self-management of chronic pain is prioritised by the planned NICE guideline. Pain management (young people and adults)
with a focus on initial assessment and management of persistent pain in young people and adults.
We propose titles in paracetamol, ibuprofen, diclofenac, other NSAIDs, and codeine, an overview review on pain in the community,
2 rapid reviews on the pharmacotherapy of chronic pain, and cancer pain, and an update of psychological treatments for chronic pain.
Key outcomes
The final titles: (1) opioids for cancer-related pain (Wiffen 2017a), (2) opioids for chronic non-cancer pain (Cooper 2017a), (3)
antiepileptic drugs for chronic non-cancer pain (Wiffen 2017b), (4) antidepressants for chronic non-cancer pain (Cooper 2017b), (5)
Non-steroidal anti-inflammatory drugs (NSAIDs) for chronic non-cancer pain (Eccleston 2017), (6) Non-steroidal anti-inflammatory
drugs (NSAIDs) for cancer-related pain (Cooper 2017c - this review), (7) paracetamol for chronic non-cancer pain (Cooper 2017c).
PICO
Patients : children, aged 3 to 12, chronic pain defined as pain persisting for 3 months (NB: now changed to: birth to 17 years to
include infants, children and adolescents).
Interventions : by drug class including antiepileptic drugs, antidepressants, opioids, NSAIDs, and paracetamol.
Comparisons : maintain a separation of cancer and non-cancer, exclude headache, in comparison with placebo and or active control.
Outcomes : we will adopt the IMMPACT criteria.
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Appendix 2. Methodological considerations for chronic pain
There have been several recent changes in how the efficacy of conventional and unconventional treatments is assessed in chronic painful
conditions. The outcomes are now better defined, particularly with new criteria for what constitutes moderate or substantial benefit
(Dworkin 2008); older trials may only report participants with ’any improvement’. Newer trials tend to be larger, avoiding problems
from the random play of chance. Newer trials also tend to be of longer duration, up to 12 weeks, and longer trials provide a more
rigorous and valid assessment of efficacy in chronic conditions. New standards have evolved for assessing efficacy in neuropathic pain,
and we are now applying stricter criteria for the inclusion of trials and assessment of outcomes, and are more aware of problems that
may affect our overall assessment. We summarise some of the recent insights that must be considered in this new review.
1. Pain results tend to have a U-shaped distribution rather than a bell-shaped distribution. This is true in acute pain (Moore 2011a;
Moore 2011b), back pain (Moore 2010d), and arthritis (Moore 2010c), as well as in fibromyalgia (Straube 2010); in all cases average
results usually describe the experience of almost no-one in the trial. Data expressed as averages are potentially misleading, unless they
can be proven to be suitable.
2. As a consequence, we have to depend on dichotomous results (the individual either has or does not have the outcome) usually
from pain changes or patient global assessments. The Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials
(IMMPACT) group has helped with their definitions of minimal, moderate, and substantial improvement (Dworkin 2008). In
arthritis, trials of less than 12 weeks’ duration, and especially those shorter than eight weeks, overestimate the effect of treatment
(Moore 2010c); the effect is particularly strong for less effective analgesics, and this may also be relevant in neuropathic-type pain.
3. The proportion of patients with at least moderate benefit can be small, even with an effective medicine, falling from 60% with
an effective medicine in arthritis to 30% in fibromyalgia (Moore 2009; Moore 2010c; Moore 2013b; Moore 2014b; Straube 2008;
Sultan 2008). A Cochrane Review of pregabalin in neuropathic pain and fibromyalgia demonstrated different response rates for
different types of chronic pain (higher in diabetic neuropathy and postherpetic neuralgia and lower in central pain and fibromyalgia)
(Moore 2009). This indicates that different neuropathic pain conditions should be treated separately from one another, and that
pooling should not be done unless there are good grounds for doing so.
4. Individual patient analyses indicate that patients who get good pain relief (moderate or better) have major benefits in many
other outcomes, affecting quality of life in a significant way (Moore 2010b; Moore 2014a).
5. Imputation methods such as last observation carried forward (LOCF), used when participants withdraw from clinical trials, can
overstate drug efficacy especially when adverse event withdrawals with drug are greater than those with placebo (Moore 2012).
Appendix 3. MEDLINE search strategy (via Ovid)
1. exp Pain/
2. pain.tw.
3. 1 or 2
4. exp Neoplasms/
5. (cancer* or neoplas* or tumo* or carcinoma* or hodgkin* or nonhodgkin* or adenocarcinoma* or leuk?emia* or metasta* or
malignan* or lymphoma* or sarcoma* or melanoma* or myeloma* or oncolog*).tw.
6. 4 or 5
7. exp Child/ or exp adolescent/
8. (child* or boy* or girl* or adolescen* or teen* or toddler* or preschooler* or pre-schooler*).tw.
9. 7 or 8
10. 13 and 6 and 9
11. exp Anti-Inflammatory Agents, Non-Steroidal/
12. NSAID*.tw.
13. “non-steroidal anti-inflammatory drug*”.tw.
14. (ibuprofen or aspirin or naproxen or fenoprofen or ketoprofen or tiaprofenic acid or diclofenac or aceclofenac or etodolac or
indometacin or mefenamic acid or meloxicam or nabumeton or phenylbutazone or piroxicam or sulindac or tenoxicam or tolfenamic
acid or ketorolac or parecoxib or celecoxib or etoricoxib).tw.
15. “non-steroidal anti-inflammatory agent*”.tw.
16. or/11-15
17. randomized controlled trial.pt.
18. controlled clinical trial.pt.
19. randomized.ab.
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20. placebo.ab.
21. drug therapy.fs.
22. randomly.ab.
23. trial.ab.
24. groups.ab.
25. 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24
26. exp animals/ not humans.sh.
27. 25 not 26
28. 10 and 16 and 27
Appendix 4. Embase search strategy (via Ovid)
1. exp Pain/
2. pain.tw.
3. 1 or 2
4. exp Neoplasms/
5. (cancer* or neoplas* or tumo* or carcinoma* or hodgkin* or nonhodgkin* or adenocarcinoma* or leuk?emia* or metasta* or
malignan* or lymphoma* or sarcoma* or melanoma* or myeloma* or oncolog*).tw.
6. 4 or 5
7. exp Child/ or exp adolescent/
8. (child* or boy* or girl* or adolescen* or teen* or toddler* or preschooler* or pre-schooler*).tw.
9. 7 or 8
10. 3 and 6 and 9
11. exp Anti-Inflammatory Agents, Non-Steroidal/
12. NSAID*.tw.
13. “non-steroidal anti-inflammatory drug*”.tw.
14. (ibuprofen or aspirin or naproxen or fenoprofen or ketoprofen or tiaprofenic acid or diclofenac or aceclofenac or etodolac or
indometacin or mefenamic acid or meloxicam or nabumeton or phenylbutazone or piroxicam or sulindac or tenoxicam or tolfenamic
acid or ketorolac or parecoxib or celecoxib or etoricoxib).tw.
15. “non-steroidal anti-inflammatory agent*”.tw.
16. or/11-15
17. random$.tw.
18. factorial$.tw.
19. crossover$.tw.
20. cross over$.tw.
21. cross-over$.tw.
22. placebo$.tw.
23. (doubl$ adj blind$).tw.
24. (singl$ adj blind$).tw.
25. assign$.tw.
26. allocat$.tw.
27. volunteer$.tw.
28. Crossover Procedure/
29. double-blind procedure.tw.
30. Randomized Controlled Trial/
31. Single Blind Procedure/
32. or/17-31
33. (animal/ or nonhuman/) not human/
34. 32 not 33
35. 10 and 16 and 34
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Appendix 5. CENTRAL search strategy (via CRSO)
1. MESH DESCRIPTOR Pain EXPLODE ALL TREES
2. pain:TI,AB,KY
3. #1 OR #2
4. MESH DESCRIPTOR Neoplasms EXPLODE ALL TREES
5. ((cancer* or neoplas* or tumo* or carcinoma* or hodgkin* or nonhodgkin* or adenocarcinoma* or leuk?emia* or metasta* or
malignan* or lymphoma* or sarcoma* or melanoma* or myeloma* or oncolog*)):TI,AB,KY
6. #4 OR #5
7. MESH DESCRIPTOR Child EXPLODE ALL TREES
8. MESH DESCRIPTOR adolescent EXPLODE ALL TREES
9. ((child* or boy* or girl* or adolescen* or teen* or toddler* or preschooler* or pre-schooler*)):TI,AB,KY
10. #7 OR #8 OR #9
11. #3 AND #6 AND #10
12. MESH DESCRIPTOR Anti-Inflammatory Agents, Non-Steroidal EXPLODE ALL TREES
13. NSAID*:TI,AB,KY
14. (“non-steroidal anti-inflammatory drug*”):TI,AB,KY
15. ((ibuprofen or aspirin or naproxen or fenoprofen or ketoprofen or tiaprofenic acid or diclofenac or aceclofenac or etodolac or
indometacin or mefenamic acid or meloxicam or nabumeton or phenylbutazone or piroxicam or sulindac or tenoxicam or tolfenamic
acid or ketorolac or parecoxib or celecoxib or etoricoxib)):TI,AB,KY
16. (“non-steroidal anti-inflammatory agent*”):TI,AB,KY
17. #12 OR #13 OR #14 OR #15 OR #16
18. #11 AND #17
Appendix 6. GRADE guidelines
Some advantages of utilising the GRADE process are (Guyatt 2008):
• transparent process of moving from evidence to recommendations;
• clear separation between quality of evidence and strength of recommendations;
• explicit, comprehensive criteria for downgrading and upgrading quality of evidence ratings; and
• clear, pragmatic interpretation of strong versus weak recommendations for clinicians, patients, and policy makers.
The GRADE system uses the following criteria for assigning grades of evidence:
• high: we are very confident that the true effect lies close to that of the estimate of the effect;
• moderate: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but
there is a possibility that it is substantially different;
• low: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect;
and
• very low: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the
estimate of effect.
We will decrease the grade if there is:
• serious (-1) or very serious (-2) limitation to study quality;
• important inconsistency (-1);
• some (-1) or major (-2) uncertainty about directness;
• imprecise or sparse data (-1); or
• high probability of reporting bias (-1).
We will increase the grade if there is:
• strong evidence of association - significant relative risk of > 2 (< 0.5) based on consistent evidence from two or more
observational studies, with no plausible confounders (+1);
• very strong evidence of association - significant relative risk of > 5 (< 0.2) based on direct evidence with no major threats to
validity (+2);
• evidence of a dose response gradient (+1); or
• all plausible confounders would have reduced the effect (+1).
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WH A T ’ S N E W
Last assessed as up-to-date: 21 February 2017.
Date Event Description
14 August 2017 Amended References for some reviews from the suite amended to reflect correct publication Issue
C O N T R I B U T I O N S O F A U T H O R S
TC and CE registered the title.
TC, PW and CE wrote the template protocol for the suite of children’s reviews of which this review is a part.
All authors contributed to writing the protocol and all authors agreed on the final version.
All authors were responsible for data extraction, analysis, and writing of the discussion for the full review.
All authors will be responsible for the completion of updates.
D E C L A R A T I O N S O F I N T E R E S T
CE: none known.
TC: none known.
BA: none known; BA is a specialist anaesthetist and intensive care physician and manages the perioperative care of children requiring
surgery and those critically ill requiring intensive care.
MCG: none known; MCG is a specialist paediatric pain and palliative care physician and treats patients with complex pain.
LH: none known.
GL: none known; GL is a specialist paediatric oncologist and paediatric pain physician and manages patients with cancer and cancer
pain.
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
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External sources
• National Institute for Health Research (NIHR), UK.
NIHR Programme Grant, Award Reference Number: 13/89/29 (Addressing the unmet need of chronic pain: providing the evidence
for treatments of pain)
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We altered the MEDLINE search strategy after some discussion with the Cochrane Childhood Cancer Group. The search strategies
for Embase and CENTRAL were then modelled on the minor changes.
Minor changes to background wording and details of examples.
Studies with < 10 participants per treatment arm were not considered for inclusion in this review, as is standard practice for this group.
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